癫痫节律标志物及时辰治疗

注册号:

Registration number:

ChiCTR2400084486 

最近更新日期:

Date of Last Refreshed on:

2024-05-17 14:25:03 

注册时间:

Date of Registration:

2024-05-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

癫痫节律标志物及时辰治疗

Public title:

Epilepsy rhythm markers and chronotherapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

癫痫节律标志物及时辰治疗

Scientific title:

Epilepsy rhythm markers and chronotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张天鹏 

研究负责人:

隋立森 

Applicant:

Tianpeng Zhang 

Study leader:

Lisen Sui 

申请注册联系人电话:

Applicant telephone:

+86 132 4916 1031

研究负责人电话:

Study leader's
telephone:

+86 137 1158 0891

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Zhangtp20@163.com

研究负责人电子邮件:

Study leader's E-mail:

13711580891@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市番禺区外环东路232号

研究负责人通讯地址:

广东省广州市番禺区大学城内环西路55号

Applicant address:

No. 232 Waihuan East Road, Panyu District, Guangzhou City, Guangdong Province

Study leader's address:

No. 55 Inner Ring West Road, University City, Panyu District, Guangzhou City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学中药学院

Applicant's institution:

School of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine

研究负责人所在单位:

广东省中医院

Affiliation of the Leader:

Guangdong Provincial Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ZF2023-471-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024-01-19 00:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

No. 111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8188 7233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市番禺区大学城内环西路55号

Primary sponsor's address:

No. 55 Inner Ring West Road, University City, Panyu District, Guangzhou City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院大学城医院

具体地址:

广东省广州市番禺区大学城内环西路55号

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine University City Hospital

Address:

No. 55 Inner Ring West Road, University City, Panyu District, Guangzhou City, Guangdong Province

经费或物资来源:

广东省自然科学基金杰出青年项目

Source(s) of funding:

Outstanding Youth Program of Guangdong Provincial Natural Science Foundation

研究疾病:

癫痫  

Target disease:

epilepsy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确青少年肌阵挛癫痫、BECTS或额叶癫痫患者的节律规律,节律性发作的癫痫患者采用时辰治疗方案比常规治疗方案疗效更优或者副作用更小。  

Objectives of Study:

Clarify the rhythmic patterns of adolescent myoclonic epilepsy, BECTS, or frontal lobe epilepsy patients. For epilepsy patients with rhythmic seizures, the use of chronotherapy is more effective or has fewer side effects than conventional treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①  患有智力障碍、器质性脑损伤或癫痫发作。 ②  处于癫痫持续状态的参与者, ③  并发严重感染、脑血管疾病、恶性肿瘤等神经系统疾病,心、肝、肾等器官严重功能障碍,精神障碍的参加者, ④  被诊断为晕厥、歇斯底里或其他非癫痫发作的参与者, ⑤  怀孕或哺乳期的参与者, ⑥  患者有重复经颅磁刺激的禁忌证。

Exclusion criteria:

① Suffering from intellectual disabilities, organic brain injury, or epileptic seizures. ② Participants in a state of persistent epilepsy, ③ Participants with severe infections, cerebrovascular diseases, malignant tumors and other neurological diseases, severe dysfunction of organs such as the heart, liver, and kidneys, and mental disorders, ④ Participants diagnosed with syncope, hysteria, or other non epileptic seizures, ⑤ Pregnant or lactating participants, ⑥ The patient has contraindications for repeated transcranial magnetic stimulation.

研究实施时间:

Study execute time:

From 2024-05-31 00:00:00 To 2026-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-31 00:00:00 To 2026-04-01 00:00:00

干预措施:

Interventions:

组别:

时辰治疗组

样本量:

75

Group:

Chronological treatment group

Sample size:

干预措施:

早晚分别给予不同剂量的丙戊酸钠

干预措施代码:

Intervention:

Administer different doses of sodium valproate in the morning and evening, respectively

Intervention code:

组别:

常规治疗组

样本量:

75

Group:

Conventional treatment group

Sample size:

干预措施:

早晚分别给予相同剂量的丙戊酸钠

干预措施代码:

Intervention:

Administer the same dose of sodium valproate in the morning and evening separately

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院大学城医院 

单位级别:

三甲 

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine University City Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

癫痫无发作比例

指标类型:

主要指标

Outcome:

The proportion of epilepsy without seizures

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗保留时间

指标类型:

次要指标

Outcome:

Treatment retention time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无发作的药物剂量水平

指标类型:

次要指标

Outcome:

Drug dosage levels without seizures

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应发生率

指标类型:

次要指标

Outcome:

Adverse reaction incidence rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

唾液

组织:

Sample Name:

Saliva

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

口腔上皮细胞

组织:

Sample Name:

Oral epithelial cells

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 5 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计师产生随机序列 ,试验设计者决定哪一类随机数字为治疗组 ,哪一类为对照组 ;他们均不参加纳人受试对象和以后的试验过程。编制一张分配序列表,表分3列,第1列为纳入对象序号,第2列为随机数字,第3列为分组标识。根据随机数字确定组别,采用计算机电子表格,计算机加密。

Randomization Procedure (please state who generates the random number sequence and by what method):

The statistician generates a random sequence, and the trial designer decides which type of random number is the treatment group and which type is the control group; They did not participate in the recruitment of subjects and the subsequent experimental process. Prepare an allocation sequence table consisting of three columns, with the first column indicating the inclusion object number, the second column indicating random numbers, and the third column indicating grouping identification. Determine the group based on random numbers, use a computer spreadsheet, and encrypt it.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

NONE

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-05-17 14:24:59